Truly Technologies

Truly Technologies is a University of Washington spinout founded in 2021, focusing on a novel osmotic bioprocessing platform. The company's passive, power-free device concentrates and purifies biomolecules like diagnostic biomarkers and therapeutic nanoparticles with high yield and purity, addressing key bottlenecks in sample preparation. Targeting the digital health and AI/machine learning sectors, Truly aims to enable more sensitive diagnostics and efficient biomanufacturing through its versatile and scalable technology. The company is in an early, pre-revenue stage, building partnerships and validating its platform across multiple applications.

Passive osmotic processor using a semipermeable membrane and polymer solution to concentrate and purify biomolecules via osmotic pressure difference. The device features an ultra-thin fluid layer design for rapid processing, is scalable from microliters to liters, requires no power, and uses selectable membrane pore sizes for different targets.

Truly competes with established sample preparation methods like centrifugal filtration, dialysis, and tangential flow filtration from large players like Thermo Fisher and Sartorius. Its differentiation lies in passive operation, speed, simplicity, and cost, but it must prove superior performance and reliability to displace incumbent technologies.